Percutaneous HAM-splenoportoscintigraphy, porta-systemic shunting and hepatic sinusoidal pressure in cirrhosis of the liver.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to J Weits.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
A 31-year-old homosexual man with AIDS, bilateral cytomegalovirus (CMV) retinitis and optic neuritis in one eye, was treated with DHPG. The drug is an acyclic nucleoside analogue of guanosine with antiviral activity. The visual acuity at the start of treatment was R.E.: no light perception and L.E.: 1.25. There was bilateral regression of retinal exudates on DHPG 5 mg/kg twice a day during 2 weeks. The visual result however was poor because of the optic nerve involvement, which did not improve during DHPG treatment. Four weeks later there was a recurrence of retinitis with the development of exudative retinal detachment in the eye with optic neuritis, despite maintenance therapy of 5 mg/kg once a day Monday through Friday. The dose was increased to 5 mg/kg twice a day, but after 1 week treatment had to be discontinued because of neutropenia. Eight days later treatment was restarted with DHPG 5 mg/kg in a single daily dose during 17 days, which led to remission of retinitis but retinal reattachment did not occur. Thereafter maintenance therapy was continued. Visual acuity remained unchanged. DHPG appears to be effective in treating cytomegalovirus retinitis but long-term suppressive therapy would be necessary to prevent recurrence of the retinitis.
The cytomegalovirus (CMV) antigenemia test is a new direct method of diagnosing active CMV infection. The test is based on immunocytochemical detection of CMV immediate early antigens in blood leukocytes. Technical aspects and pitfalls are discussed. The diagnostic merits of the test are compared with those of other methods, such as isolation of virus from blood, serologic determinations, and the polymerase chain reaction. Overall, active CMV infection can be diagnosed by the detection of CMV antigenemia with a sensitivity and specificity of greater than or equal to 90%, whereas sensitivity is 100% in symptomatic patients. On average, the test provides diagnostic information at least 1 week earlier than other established methods. Moreover, the level of CMV antigenemia appears to be related to the severity of disease and to be inversely related to the level of host immunocompetence. It is concluded that (1) the test is useful for the early and rapid diagnosis of life-threatening CMV infection in immunodeficient patients, (2) the test could be a useful tool in the study of the immunopathophysiology of CMV disease, and (3) the antigenemia test may be a promising marker for monitoring disease activity and its response to specific chemotherapy.